Abstract. PUMA (p53 upregulated modulator of apoptosis), a member of the B-cell lymphoma 2 (Bcl-2) protein family, is a pro-apoptotic protein. PUMA expression is modulated by the tumor suppressor p53. PUMA has a role in rapid cell death via p53-dependent and -independent mechanisms. To evaluate whether p53 is required for PUMA-mediated apoptosis in prostate cancer cells, p53 protein was silenced in human prostate cancer PC-3 cells by using p53 small interfering RNA (siRNA). The interference efficiency of p53 on RNA and protein levels was detected by reverse transcription-quantitative polymerase chain reaction and western blotting. Cell proliferation and p21 expression were subsequently examined by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay and western blot analysis, respectively. p53-silenced or control PC-3 cells were transfected with pCEP4-(hemagglutinin)-PUMA plasmid, or non-carrier plasmid. Enzyme-linked immunosorbent assay was used to determine cell apoptosis by measuring histone release and caspase-3 activation, and MTT assay was used to measure cell viability. In addition, the expression of pro-apoptosis protein Bax and anti-apoptosis protein Bcl-2 were evaluated. The results of the present study revealed that p53 siRNA significantly suppressed p53 RNA and protein expression in PC-3 cells. Deficiency of p53 increased the cell growth rate and decreased p21 expression. However, PUMA overexpression remained able to induce apoptosis in p53-silenced and control cells by increasing Bax expression and decreasing Bcl-2 expression, leading to the activation of caspase-3. These results suggest that PUMA may mediate apoptosis of prostate cancer PC-3 cells, potentially independently of p53. Furthermore, PUMA gene treatment to induce cancer cell apoptosis may be more efficient compared with p53-dependent apoptosis, where loss of p53 expression or function may lead to limited efficacy of PUMA expression. Therefore, the present study proposes the significant hypothesis that increasing PUMA expression may be an effective approach for the treatment of prostate cancer, regardless of p53 status.

Introduction

Prostate cancer is one of the most common types of cancer in men, with >40,000 new cases diagnosed every year in the UK (1). Prostate cancer is typically slow-growing and the majority of men do not notice the symptoms until the cancer has become large enough to press against the urethra and interfere with urination. The standard treatment approach for prostate cancer is surgical removal of the gland or prostatectomy, coupled with chemotherapy and radiotherapy (1). These approaches may be followed by hormone therapy, which interrupts the cancer cells’ supply of testosterone, and therefore inhibits their ability to grow. The high incidence of prostate cancer and the lack of treatment efficacy of traditional treatment seriously affects the normal life of men (1).

Tumors are caused by abnormal cell proliferation, differentiation and apoptosis due to the activation of certain proto-oncogenes, inactivation of tumor suppressors and changes to apoptosis-associated genes (2,3). p53 upregulated modulator of apoptosis (PUMA), also known as Bcl-2-binding component 3 (BBC3), is a pro-apoptotic protein and is a member of the B-cell lymphoma 2 (Bcl-2) protein family (4,5). The underlying mechanism of PUMA-mediated apoptosis has been extensively evaluated (6-9). The tumor suppressor protein p53 has a dual role associated with PUMA gene expression and function. The efficiency of PUMA as an apoptosis-inducing protein and its association with p53 depends on the cell lineage, the status of p53 (deficiency vs. mutation) and the type of stimulus. Thus, PUMA activates apoptosis through p53-dependent and -independent signaling pathways, induced by a range of signals (10-13). In the majority of cell types, p53 expression results in increased PUMA gene expression, and subsequent PUMA-mediated apoptosis requires functional p53. The majority of PUMA-induced apoptosis occurs via...
activation of p53 (10-12). p53 is activated by survival signals, including glucose deprivation (14), which leads to an increase in the expression levels of PUMA. PUMA expression leads to apoptosis by displacement of p53 from Bcl-extra large (XL), allowing p53 to increase mitochondrial permeability (15). The subsequent increase in PUMA levels is able to induce apoptosis via mitochondrial dysfunction. p53, as well as PUMA, is activated as a result of DNA damage caused by a range of genotoxic agents. Alternative agents that are able to induce p53-dependent apoptosis are neurotoxins (16,17), proteasome inhibitors (18), microtubule poisons (19) and transcription inhibitors (20). However, in certain cell types, PUMA apoptosis may additionally be induced independently of p53 activation by alternative stimuli, including oncogenic stress (21,22), growth factor and/or cytokine withdrawal and kinase inhibition, ER stress, altered redox status, ischemia, immune modulation, and infection (23,24).

Regardless of the method of signaling pathway activation, PUMA interacts with the anti-apoptotic proteins Bcl-2, Bcl-xL, Bcl-W and myeloid cell leukemia 1, via its BH3 structural domain, to induce cell apoptosis (5,25) and obstructs the interaction of these proteins with the pro-apoptotic molecules Bcl-2-like protein 4 (Bax) and Bcl-2 homologous antagonist/killer (Bak), therefore freeing Bax and/or Bak, which are subsequently able to signal apoptosis to the mitochondria (5,23,25). Following mitochondrial dysfunction, the caspase cascade is activated, which leads to cell death (23).

A number of studies have demonstrated that PUMA functioning is altered or absent in cancer cells (26,27). In addition, the loss of p53-mediated apoptosis has been implicated as a significant occurrence during tumor progression (26,28). The majority of cancer types exhibit p53 gene deficiency or mutations, meaning that the application of gene therapies that target this gene is not possible (28). However, an alternative potential method may involve focusing on PUMA as a therapeutic target, leading to the induction of apoptosis in cancer cells. In the present study, the influence of exogenous PUMA on proliferation and apoptosis was investigated in prostate cancer PC-3 cells, and it was determined whether PUMA requires functional p53 in these cells.

Materials and methods

Cell culture and treatments. PC-3 human prostate adenocarcinoma cancer cells were purchased from American Type Culture Collection (Manassas, VA, USA). Cells were cultured with RPMI-1640 supplemented with 10% heat-inactivated fetal bovine serum (Gibco; Thermo Fisher Scientific, Inc., Waltham, MA, USA). Cells were maintained in culture at 37˚C in a humidified atmosphere of 5% CO2 and 95% humidity.

Scrambled RNA and p53 small interfering RNA (siRNA) were obtained from Dharmacon (GE Healthcare Life Sciences, Chalfont, UK). pCEP4-[hemagglutinin (HA)] 2-PUMA recombinant plasmid and non-carrier plasmid pCEP4-(HA) 2-C1 were kindly provided by Dr B. Vogelstein (Johns Hopkins Oncology Center, Baltimore, MD, USA). A total of 2x10⁶ cells were transfected by scrambled RNA or p53 siRNA using Lipofectamine 2000 (Invitrogen; Thermo Fisher Scientific, Inc.) for 72 h according to the manufacturer’s protocol. Subsequently, the cells were cultured in 100-mm dishes and transfected by PUMA or pCEP4 plasmid and left to grow for 24 h, prior to detection.

Reverse transcription-quantitative polymerase chain reaction (RT-qPCR). RNA was isolated from PC-3 cells with the Total RNA Isolation kit (A&A Biotechnology, Gdynia, Poland) according to the manufacturer’s protocol. First strand complementary DNA (cDNA) was obtained by reverse transcription of 1 µg of total RNA with the RevertAid First Strand cDNA synthesis kit (Thermo Fisher Scientific, Inc.) according to the manufacturer’s protocol. Amplification of the cDNA was performed using the TaqMan® Gene Expression Assay (Applied Biosystems; Thermo Fisher Scientific, Inc.), with fluorogenic fluorescein amide-labeled probes, sequence-specific primers of gene coding p53 and the internal control glyceraldehyde-3-phosphate dehydrogenase (GAPDH), according to the manufacturer’s protocol. Samples with no cDNA or no reverse transcription were used as controls. Genes were amplified by a first step of 120 sec at 95˚C, followed by 45 cycles of 30 sec at 95˚C, 30 sec at 60˚C and 30 sec at 72˚C. The real-time fluorescence detection was performed with the ABI PRISM 7700 Sequence Detector (Perkin-Elmer Applied Biosystem; Thermo Fisher Scientific, Inc.). Fold differences in p53 expression, normalized to the level of GAPDH, were calculated with the formula 2 DeltaCq (29). Relative quantities of messenger RNA (mRNA) in siRNA-treated cells were indicated as a percentage of the amount of mRNA in the untreated cells.

Western blotting. Cells were lysed in cell lysis buffer (50 mM HEPES, pH 8.0; 150 mM NaCl; 1% Triton X-100; 10% glycerol; 1 mM MgCl2; 1.5 mM ethylenediaminetetraacetic acid; 20 mM β-glycerophosphate; 50 mM NaF; 1 mM NaVO3; 10 µg/ml aprotonin; 1 µM pepstatin A and 1 mM phenylmethylsulfonyl fluoride; catalogue no. P0013; Beyotime Institute of Biotechnology, Haimen, China) containing a protease inhibitor cocktail (Roche Applied Science, Madison, WI, USA). Proteins were isolated from the total cells using 14,000 x g centrifugation for 10 min at 4˚C and the supernatant was collected. Protein samples (50 µg) were separated by 12% sodium dodecyl sulfate polyacrylamide gel electrophoresis and transferred to Immobilon-P polyvinyl difluoride membranes (EMD Millipore, Billerica, MA, USA). The membrane was blocked with 5% non-fat dried milk in Tris-buffered saline with Tween 20 for 1 h at room temperature and then incubated overnight at 4˚C with mouse monoclonal anti-p53 (1:1,000 dilution; catalogue no. sc-126), anti-HA tag (1:2,000 dilution; catalogue no. sc-7392), rabbit polyclonal anti-p21 (1:2,000 dilution; catalogue no. sc-397), anti-Bcl-2 (1:2,000 dilution; catalogue no. sc-783), anti-Bax (1:2,000 dilution; catalogue no. sc-526) and anti-GAPDH (1:2,000 dilution; catalogue no. sc-25778) antibodies (Santa Cruz Biotechnology Inc., Dallas, TX, USA). Goat anti-mouse (1:2,000 dilution; catalogue no. sc-205) and goat anti-rabbit immunoglobulin G (1:2,000 dilution; catalogue no. sc-2004) were used for incubation for 2 h at room temperature. Enhanced chemiluminescence-detecting reagent (GE Healthcare Life Sciences) was used to visualize the membranes. The protein blots were quantified by densitometry using QuantityOne software (Bio-Rad Laboratories, Inc., Hercules, CA, USA).
USA), and the amounts were expressed relative to the internal reference GAPDH.

**Cell proliferation assay.** Cell proliferation was assessed by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. Briefly, cells were seeded (1x10^4 cells per well) into a 96-well flat-bottom plate following transfection. Cells were cultured at 37˚C in an atmosphere of 5% CO_2 for 48 h, followed by an additional 4 h of incubation subsequent to the addition of 20 µl 5 mg/ml MTT (Sigma-Aldrich; Merck Millipore, Darmstadt, Germany) to each well. Cells were lysed by addition of 200 µl dimethylsulfoxide (Sigma-Aldrich; Merck Millipore). Absorbance was measured at 490 nm with an enzyme-linked immunosorbent assay (ELISA) reader (Tecan Austria GmbH, Grödig, Austria).

**Cell apoptosis assay.** Apoptosis was assessed using a Cell Death Detection ELISA PLUS kit (Thermo Fisher Scientific, Inc.). PUMA or non-carrier plasmids were transfected into p53 siRNA-transfected or scrambled siRNA-transfected cells. The cells were subsequently cultured at 4.5x10^5 cells per well in 6-well plates. A total of 8 h later, the cells were lysed and assayed for western blotting.

**Statistical analysis.** SPSS (version 11.0; SPSS, Inc., Chicago, IL, USA) was used to analyze the experimental data. Data are presented as the mean ± standard error. Statistical significance was analyzed by Student’s t-test using SPSS 11.0 software (SPSS, Inc., Chicago, IL, USA). All experiments were repeated at least 3 times. P<0.05 was considered to indicate a statistically significant difference.

**Results**

**Silencing of p53 protein in prostate cancer PC-3 cells.** To determine whether siRNA was able to knockdown p53 expression in cultured prostate cancer PC-3 cells, p53 RNA expression was examined by RT-qPCR (Fig. 1A) and protein expression was detected by western blotting (Fig. 1B). A representative time course and dose response is presented in Fig. 1B. The results demonstrated that the relative p53 mRNA amount was significantly decreased in p53 siRNA-treated cells relative to non-silencing scrambled siRNA-transfected cells (P=0.002; Fig. 1A), and the residual expression of p53 protein in the cells with 2 µg of siRNA transfected for 72 h was markedly suppressed. For the subsequent experiments,
2 µg of siRNA transfected for 72 h was selected as the optimum condition.

Effect of p53 deficiency on cellular function. The functional effects of p53 knockdown were assessed by detection of cell proliferation and p21 protein expression, which is normally induced by p53 (30). The results revealed that the growth of prostate cancer PC-3 cells was increased following p53 siRNA transfection compared with the mock-transfected cells (P=0.007; Fig. 2A) and the expression of p21 protein was blocked in p53-silenced cells (Fig. 2B). These data confirmed that p53 deficiency with siRNA contributed to relevant functional alterations, which were consistent with p53 interference.

PUMA induces apoptosis independently of p53. To confirm whether p53 was required for PUMA-induced apoptosis, prostate cancer PC-3 cells were transfected with p53 siRNA. Once p53 reached its minimum level of expression 72 h subsequent to transfection, cells were transfected with pCEP4-(HA)-PUMA, or empty pCEP4 plasmids. As demonstrated in Fig. 3A and B, PUMA-induced apoptosis was assessed by measuring cell viability or histone release. The results indicated that p53-silenced cells did not show significant differences in PUMA-induced apoptosis levels compared with scrambled siRNA-transfected cells (P=0.095 and P=0.126; Fig. 3A and B, respectively) PUMA-induced apoptosis in scrambled siRNA-transfected cells was similar to that in p53 siRNA-transfected cells. As additional evidence of PUMA-mediated apoptosis, caspase-3 activation was evaluated in p53-deficient PC-3 cells. The data demonstrated that

Figure 3. PUMA induces apoptosis in p53-deficient PC-3 cells. PC-3 cells were treated with 2 µg siRNA for 72 h, and subsequently were transfected with 8 µg PUMA or pCEP4 plasmid. (A) PUMA-induced apoptosis was initially evaluated by inhibition of cell survival. 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay was performed 24 h subsequent to complementary DNA transfection in siRNA-treated PC-3 cells. The fold inductions are shown relative to mock-transfected cells. (B) DNA fragmentation was determined by histone release. Histone release was measured by enzyme-linked immunosorbent assay in samples collected 9 h subsequent to the second transfection. The fold induction of DNA fragmentation in PC-3 cells transfected with PUMA plasmids is shown relative to the control value of pCEP4-transfected cells. (C) Caspase-3 activation was determined in control and p53-deficient PC-3 cells 8 h subsequent to transfection with PUMA. *P<0.05, **P<0.01. PUMA, p53 upregulated modulator of apoptosis; siRNA, small interfering RNA; sc, control.

Figure 4. Influence of exogenous PUMA on Bcl-2 and Bax protein expression in human prostate cancer PC-3 cells. (A) Exogenous PUMA expression, and alterations in Bax or Bcl-2 protein expression, in control and p53-deficient PC-3 cells were assessed by western blot analysis, respectively, with anti-HA, anti-Bax or anti-Bcl-2 antibodies. (B) Bax/Bcl-2 ratios were counted by the quantitation of Bax protein blots divided by the quantitation of Bcl-2 protein blots. *P<0.01 vs. pCET4 empty vector-transfected control cells. Data are presented as the mean ± standard error. PUMA, p53 upregulated modulator of apoptosis; Bcl-2, B-cell lymphoma 2; Bax, bcl-2-like protein 4; HA, hemagglutinin; sc, control; siRNA, small interfering RNA; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; sip53; siRNA duplexes.
PUMA induced higher caspase-3 activation in p53-deficient PC-3 cells compared with scrambled siRNA-transfected cells (P=0.045 and P=0.021; Fig. 3C), suggesting that PUMA did not require the participation of p53 to induce this apoptosis signaling pathway.

Influence of exogenous PUMA on Bcl-2 and Bax protein expression in human prostate cancer PC-3 cells. The western blot analysis results revealed HA-PUMA protein expression in scrambled siRNA-transfected and p53 siRNA-transfected cells, indicating successful transfection (Fig. 4A). Compared with the control transfected with empty pCEP4 plasmid, the PUMA group demonstrated significantly increased expression of the pro-apoptotic protein Bax and significantly reduced expression of the anti-apoptotic protein Bcl-2, regardless of p53 deficiency (Fig. 4A). In addition, the Bax/Bcl-2 ratios were significantly increased compared with the control with empty plasmid pCEP4 (P=0.003 and P=0.002; Fig. 4B). These results verified that PUMA was able to engage the apoptotic signaling pathway by modulating Bcl-2 and Bax protein expression independently of p53.

Discussion

Prostate cancer is one of the most common malignant tumors in men (1). Chemotherapy kills tumor cells by activating apoptosis, while apoptotic signaling pathway defects are associated with tumor resistance to chemotherapy. Due to side effects and tumor cell insensitivities, the clinical application of chemotherapeutic drugs may be greatly restricted (31). A number of studies concerning gene therapy have attracted widespread attention (32-34). Therefore, searching for ideal target genes has become a significant issue to address.

The introduction of apoptotic genes has the potential to increase sensitivity to chemotherapy drugs. The loss of p53-mediated apoptosis has been implicated as a significant event in tumor progression. p53 is able to induce or potentiate apoptosis via a number of mechanisms, including by regulating the expression of genes that are able to participate in the apoptotic response and via transcriptionally independent means. p53 is a notable potential therapeutic gene as it is able to induce apoptosis in a range of cell types. Defects in p53 structure and function in specific unhealthy cells have been described, suggesting that forced expression of this tumor suppressor protein may be beneficial (35-38). However, enhancing p53 gene expression has been observed to have only modest efficacy (39). PUMA has a significant role in apoptotic signaling pathways, is rapidly induced by p53 and has powerful apoptosis-promoting effects. Therefore, a possible explanation for the limited efficacy of p53 gene enhancement may be that p53 did not readily induce apoptosis, potentially because PUMA expression was not increased (40). Thus, directly targeting PUMA may be an effective treatment approach to cause rapid cell death. In vitro studies have demonstrated that PUMA affects tumor cell proliferation and induces cellular apoptosis independently of p53, which has led to hopes of using PUMA for tumor therapy (41,42). Yu et al (43) reported that PUMA induced lung cancer cell apoptosis and inhibited cell proliferation via caspase activation and cytochrome c release in non-chemoradiotherapy sensitive lung cancer cells, providing evidence that PUMA is able to increase sensitivity to radiotherapy and chemotherapy drugs.

In the present study, using siRNA to decrease p53 expression demonstrated that prostate cancer PC-3 cells are sensitive to PUMA-induced death. Western blot analysis revealed that, following PUMA gene transfection, pro-apoptotic protein Bax significantly increased and anti-apoptotic protein Bcl-2 significantly decreased. In the Bcl-2 family, the ratio of pro-apoptotic to anti-apoptotic proteins is a significant factor in determining the occurrence and level of apoptosis (44). The proportion of pro-apoptotic proteins in cells additionally determines the cellular response to death signals and cell fate. It has been reported that decreased Bax protein expression is associated with the sensitivity of tumor cells to chemotherapy and the length of patient survival times (45,46). Therefore, the results of the present study suggested that PUMA was an effective mediator of apoptosis, regardless of the p53 status in PC-3 cells.

In conclusion, the results of the present study imply that PUMA is able to efficiently decrease the growth of prostate cancer PC-3 cells by promoting apoptosis independently of p53. This supports the potential use of PUMA as a novel and promising target for prostate cancer therapy. A number of cancer types exhibit deletions or mutations in p53, so PUMA shows great significance in cancer treatment. In future studies, we will verify whether the phenomenon exists in other cell lines of prostate cancer. Furthermore, the potential functions of PUMA in the chemosensitivity and treatment of prostate cancer remain to be investigated.

Acknowledgements

This study was supported by the National Natural Science Foundation of China (grant no. 81302234), the Shandong Provincial Natural Science Foundation, China (Grant no. ZR2016HP38), Projects of Medical and Health Technology Development program in Shandong province (Grant no. 2016WS0714), Science and Technology Project of Yantai (grant nos. 2016ZJH084 and 2016WS018) and the Scientific research startup Project of Binzhou Medical University (grant no. BY2014KYQD24).

References